You are here

Researchers Develop Software That Could Facilitate Drug Development

AptaTRACE helps to identify molecules that may be effective in targeted therapies

A team of researchers has developed a new software tool called AptaTRACE that could be an important advance for drug developers and other scientists who want to identify molecules that bind with high precision to targets of interest.

“This research is an excellent example of how the benefits of ‘big data’ critically depend upon the existence of algorithms that are capable of transforming such data into information,” said Teresa Przytycka, PhD, a senior investigator at the National Center for Biotechnology Information (NCBI), a division of the National Institutes of Health’s National Library of Medicine.

Aptamers are short RNA or DNA molecules that are capable of binding with high affinity and specificity to diverse biological targets. Aptamers bind to their targets because of features of their sequence and structure that are complementary to the biochemical characteristics of the target’s surface. Possible targets of aptamers include small organic molecules, proteins or protein complexes, virus surfaces, and entire cells. This broad range of targets makes aptamers candidates for a wide variety of applications, ranging from molecular biosensors to drug delivery systems to antibody replacement.

AptaTRACE is designed for use in conjunction with High-Throughput Systematic Evolution of Ligands by Exponential Enrichment (HT-SELEX), a laboratory technique for identifying aptamers. HT-SELEX allows analyses of millions of sequences to identify the candidates that undergo selection for binding to the target.

The AptaTRACE tool analyzes this data to find the common features (or “motifs”) among the sequences that bind.

AptaTRACE is the first algorithm that uses the full scope of sequencing data from a large number of selection rounds to capture sequence and structure features of aptamers that bind to the target. Such information allows researchers to better understand why some molecules bind and others do not. Understanding these binding motifs is critical for taking advantage of the aptamers identified via the HT-SELEX process to enable modifications that transform aptamers into drug delivery systems targeting specific cells, for example.

AptaTRACE is the result of a collaboration between Dr. Przytycka’s group and researchers from the Beckman Research Institute of City of Hope, Duarte, California, led by Dr. John Burnett, and from Freiburg University, Breisgau, Germany, led by Dr. Rolf Backofen. The tool can be downloaded from NCBI at: www.ncbi.nlm.nih.gov/CBBresearch/Przytycka/index.cgi#aptatools.

Research describing AptaTRACE is published in the July 27 issue of Cell Systems.

Source: National Institutes of Health; July 29, 2016.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function